McGuire W L, Cavalli F, Bonomi P, Alexieva-Figussch J
Breast Cancer Res Treat. 1985;6(3):213-20. doi: 10.1007/BF01806771.
The use of pharmacologic doses of steroid hormones to treat patients with advanced breast cancer has been standard for many years. Recently there has been increased interest in the investigation of progestational agents, largely as a result of their excellent response rate in selected patients and their minimal side effects. In this panel discussion the participants discuss the use of progestin in advanced and early breast cancer. Criteria for patient selection, such as receptor status or response to previous therapies, are analyzed, and dose-response relationship and the side effects are addressed.
多年来，使用药理剂量的类固醇激素治疗晚期乳腺癌患者一直是标准疗法。最近，人们对孕激素制剂的研究兴趣有所增加，这主要是因为它们在部分患者中有着出色的缓解率，且副作用极小。在本次小组讨论中，参与者们探讨了孕激素在晚期和早期乳腺癌中的应用。分析了患者选择标准，如受体状态或对既往治疗的反应，并讨论了剂量反应关系及副作用。
